OFW Law Celebrates 35 Years of Successes in Drug/Healthcare Privacy Practices (Part I) By Jonathan M. Weinrieb Since its inception in 1979, OFW Law’s Drugs, Biologics, and Controlled Substances and Healthcare Privacy practices have focused on myriad regulatory issues arising under FDA and broader HHS jurisdiction. We advise clients on matters ranging from Hatch-Waxman and generic drug marketing exclusivity issues, ANDAs and 505(b)(2) NDAs, to HIPAA/HITECH medical privacy matters, controlled substance laws and regulation, GMPs, drug distribution, marketing and promotion, and a variety of associated compliance and enforcement issues. Over the next several days, we will More…Image may be NSFW.
Clik here to view.
Clik here to view.